Orexo AB (SE:ORX)
:ORX
ORX Stock Chart & Stats
kr34.55
kr0.22(1.39%)
At close: 4:00 PM EST
kr34.55
kr0.22(1.39%)
Day’s Range― - ―
52-Week Rangekr12.50 - kr43.40
Previous CloseN/A
Volume4.04K
Average Volume (3M)101.19K
Market Cap
kr773.51M
Enterprise Valuekr348.52M
Total Cash (Recent Filing)kr912.40M
Total Debt (Recent Filing)kr492.20M
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Apr 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding35,127,056
10 Day Avg. Volume22,969
30 Day Avg. Volume101,192
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.12
Price to Sales (P/S)40.09
P/FCF Ratio6.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6.73
Revenue Forecast (FY)kr21.60M
Bulls Say, Bears Say
Bulls Say
Strengthened Cash PositionThe ZUBSOLV U.S. sale materially improved liquidity and produced a net cash position, providing a multi-quarter runway and tactical flexibility. A strengthened cash buffer reduces immediate refinancing pressure, funds prioritized R&D milestones, and supports orderly restructuring without urgent capital raises.
Clear R&D Milestone TimelineA defined development roadmap for AmorphOX and named programs concentrates resources and makes clinical and regulatory timelines predictable. This reduces strategic ambiguity, improves partner discussions, and enables milestone-driven financing or collaborations that can deliver durable value if trials and filings proceed as planned.
Partner/BARDA Funding EmergingSecuring BARDA and partner funding shifts program costs off the company, lowering net burn and enabling programme progression without fully dilutive financing. Structural external funding reduces funding risk for specific development programs and enhances the firm's ability to advance clinical work while preserving cash reserves.
Bears Say
Severe 2025 Revenue CollapseA dramatic decline in revenue and deeply negative margins signal a structurally weakened commercial base and fragile earnings power. Such extreme deterioration impairs the company's ability to self-fund operations, increases dependency on one-off transactions or partners, and raises long-term execution risk.
Leverage Volatility & Weak Equity HistoryMulti-year swings in leverage and periods of negative equity undermine financial flexibility and raise refinancing risk. Erratic capital structure limits strategic optionality, increases cost of capital, and makes the firm vulnerable to covenant triggers or market dislocations when pursuing clinical or commercial investments.
Weak Continued-ops Revenue And Negative EBITDAMinimal ongoing commercial revenue and a negative operating run-rate mean core operations do not cover fixed costs. This structural shortfall forces dependence on dealmaking, earn-outs, or milestone payments; such timing and execution risk can delay programs or require dilutive financing, threatening long-term plan delivery.
Orexo AB News
ORX FAQ
What was Orexo AB’s price range in the past 12 months?
Orexo AB lowest stock price was kr12.50 and its highest was kr43.40 in the past 12 months.
What is Orexo AB’s market cap?
Orexo AB’s market cap is kr773.51M.
When is Orexo AB’s upcoming earnings report date?
Orexo AB’s upcoming earnings report date is Apr 28, 2026 which is in 32 days.
How were Orexo AB’s earnings last quarter?
Orexo AB released its earnings results on Feb 05, 2026. The company reported -kr1.276 earnings per share for the quarter, missing the consensus estimate of -kr0.3 by -kr0.976.
Is Orexo AB overvalued?
According to Wall Street analysts Orexo AB’s price is currently Overvalued.
Does Orexo AB pay dividends?
Orexo AB does not currently pay dividends.
What is Orexo AB’s EPS estimate?
Orexo AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Orexo AB have?
Orexo AB has 35,127,056 shares outstanding.
What happened to Orexo AB’s price movement after its last earnings report?
Orexo AB reported an EPS of -kr1.276 in its last earnings report, missing expectations of -kr0.3. Following the earnings report the stock price went down -7.325%.
Which hedge fund is a major shareholder of Orexo AB?
Currently, no hedge funds are holding shares in SE:ORX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
ORX Company Deck
ORX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicates a materially improved financial position driven by the successful sale of ZUBSOLV U.S., resulting in strong cash proceeds (SEK 814 million net) and a net cash position (SEK 429.2 million), while allowing a strategic refocus on the AmorphOX platform and prioritized R&D milestones (OX640 pivotal trial planned Q4, OX390 in‑vivo starting Q1, IZIPRY filing target Q3/2026). However, near-term challenges remain including weak continued-operations revenue (SEK 3.3 million), negative continued-ops EBITDA (SEK -70 million for Q4), impairments (MODIA SEK 22 million), outstanding DOJ investigation risk, bond covenant remediation/possible redemption, restructuring costs in 2026, and reliance on partnerships and BARDA funding to sustain and accelerate development. Overall, the positives from the transaction, cash position, meeting 2025 metrics, and clear strategic direction outweigh the operational and legal headwinds, positioning Orexo to focus on technology-driven R&D growth but with execution and financing risks to monitor.View all SE:ORX earnings summariesTechnical Analysis
AlzeCure Pharma AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enzymatica AB
―
Enorama Pharma AB
―
Options Prices
Currently, No data available
---